Furthermore, since therapeutic T lymphocytes [e.g. tumor-infiltrating lymphocytes and chimeric antigen receptor (CAR) T lymphocytes] are generated ex vivo, they could potentially be modified with BLU-VIPR before adoptive transfer to tumor-bearing recipients in research models. The gene discussed is VIPR1; the disease is neoplasm.